Hideyuki Harada

Hideyuki Harada

Auto-generated profile, based on publicly available information

Hideyuki Harada

Radiation and Proton Therapy Center, Shizuoka Cancer Center , 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Radiation Research
Verified
Journal Article
Open access
PDF file
HHHideyuki Harada
Hideyuki Harada
HKHirohisa Katagiri
Hirohisa Katagiri
MKMinoru Kamata
Minoru Kamata
YYYasuo Yoshioka
Yasuo Yoshioka
HAHirofumi Asakura
Hirofumi Asakura
TNTetsuo Nishimura
Tetsuo Nishimura
We evaluated the radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy. 102 consecutive patients wit

14 January 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ATAkihiro Takaji
Akihiro Takaji
KMKeita Mori
Keita Mori
Tateaki NaitoTateaki Naito
Tateaki Naito
HIHisao Imai
Hisao Imai
AOAkira Ono
Akira Ono
NYNobuyuki Yamamoto
Nobuyuki Yamamoto
In locally advanced Non-Small-Cell Lung Cancer (LA-NSCLC) patients treated with chemoradiotherapy (CRT), optimal surrogate endpoint for cure has not been fully investigated.

2 August 2016 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
KSKiyomi Sumita
Kiyomi Sumita
HHHideyuki Harada
Hideyuki Harada
HAHirofumi Asakura
Hirofumi Asakura
HOHirofumi Ogawa
Hirofumi Ogawa
TOTsuyoshi Onoe
Tsuyoshi Onoe
TNTetsuo Nishimura
Tetsuo Nishimura
Re-irradiation (re-RT) of the thorax is challenging due to the impact of prior therapies on normal tissues, and there are few reports of definitive re-RT. The treatment toxicities and efficacy of re-RT are not well known. The aim of the present study was to assess the safety and efficacy of definitive re-RT of the thorax. Patients who were treated with thoracic re-RT between March 2007 and December 2014 were retrospectively analyzed. Primary and re-irradiation plans were required to have an overlap of dose distributions for the 80 % isodose level. All doses were recalculated to an equivalent dose of 2 Gy per fraction (EQD2). When possible, analysis of dose accumulation was carried out using the medical image merge (MIM) (®) software program (version 6.5, MIM Software Inc., Cleveland, OH). Administration dosages for organs at risk were defined. Fourteen (67 %) and seven (33 %) patients with non-small cell carcinoma (NSCLC) and small cell carcinoma (SCLC), respectively, were identified. The patients’ median age was 72 (range 53–85) years. Fifteen patients (71 %) had “proximal” tumors, defined as tumors at the distal 2 cm of the trachea, carina, and main bronchi. The median interval from initial RT to re-RT was 26.8 (range 11.4–92.3) months. Re-RT was delivered by X-ray beam and proton beam therapy in 20 (95 %) patients and 1 (5 %) patient, respectively. The median radiation dose of re-RT was 60 (range 54–87.5) Gy10 and 50 (range 50.0–87.5) Gy10 for patients with NSCLC and SCLC, respectively. Grade 3 acute radiation pneumonitis occurred in only one patient. There were no other serious complications. The median follow-up time was 22.1 (range 2.3–56.4) months. The median local progression-free survival time (LPFS) and overall survival time (OS) were 12.9 (95 % confidence interval (CI): 8.9–27.9) months and 31.4 (95 % CI: 16.9–45.9) months, respectively. Patients receiving ≥ 60 Gy10 at re-RT had longer LPFS (p = 0.04). Good safety with longer OS than in previous reports was demonstrated. Re-RT seems to be a promising treatment option. Further study to define the risk-benefit ratios is necessary.

1 November 2013 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
HFHiroshi Fuji
Hiroshi Fuji
USUwe Schneider
Uwe Schneider
YIYuji Ishida
Yuji Ishida
MKMasahiro Konno
Masahiro Konno
HYHaruo Yamashita
Haruo Yamashita
TNTetsuo Nishimura
Tetsuo Nishimura
To compare proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) with conformal radiation therapy (CRT) in terms of their organ doses and ability to cause secondary cancer in normal organs.

4 July 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KMKoichi Mitsuya
Koichi Mitsuya
JWJunichiro Watanabe
Junichiro Watanabe
YNYoko Nakasu
Yoko Nakasu
NHNakamasa Hayashi
Nakamasa Hayashi
HHHideyuki Harada
Hideyuki Harada
IIIchiro Ito
Ichiro Ito
Multiple new targeted agents have been developed for patients with human epidermal growth factor receptor type 2 (HER2) – positive breast cancer. Patients with HER2– positive breast cancer will develop brain metastases with greater incidence than patients with non-HER2 cancers, and many of them will undergo stereotactic radiosurgery (SRS) or other CNS radiotherapy. The interaction between radiation effects and new targeted agents is not well understood. We report two cases suggesting a novel adverse effect of T-DM1 (trastuzumab emtansine) on symptomatic enlargement of radiation necrosis (RN) after SRS. Two patients with HER2-positive breast cancer had received SRS for single brain metastasis more than 5-years ago. They had been heavily treated for HER2-positive metastatic breast cancer (trastuzumab and pacritaxel, lapatinib and capecitabine). They initiated T-DM1 therapy for progressive systematic disease 5.5 years after stereotactic irradiation, when a small RN was recognized on brain MR images of each patient. The RN lesions increased in size and became symptomatic during 13 or 14 months of T-DM1 treatment. The patients underwent surgical resection of the lesion. Pathological examination revealed necrosis, hematoma, granulation tissue and telangiectasia without neoplastic cells. A potential enhancement of RN by T-DM1 in the brain may be one of important adverse events associated with the use of T-DM1 for patients after SRS. These cases highlight the need of careful follow-up when combining new systemic targeted therapies and SRS for brain metastases.

1 August 2017 in Lung Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
HHHideyuki Harada
Hideyuki Harada
SMShigeyuki Murayama
Shigeyuki Murayama
This review summarizes the past and present status of proton beam therapy (PBT) for lung cancer. PBT has a unique characteristic called the Bragg peak that enables a reduction in the dose of normal tissue around the tumor, but is sensitive to the uncertainties of density changes. The heterogeneity in electron density for thoracic lesions, such as those in the lung and mediastinum, and tumor movement according to respiration necessitates respiratory management for PBT to be applied in lung cancer patients. There are two types of PBT – a passively scattered approach and a scanning approach. Typically, a passively scattered approach is more robust for respiratory movement and a scanning approach could result in a more conformal dose distribution even when the tumor shape is complex. Large tumors of centrally located lung cancer may be more suitably irradiated than with intensity-modulated radiotherapy (IMRT) or stereotactic body radiotherapy (SBRT). For a locally advanced lung cancer, PBT can spare the lung and heart more than photon IMRT. However, no randomized controlled trial has reported differences between PBT and IMRT or SBRT for early-stage and locally advanced lung cancers. Therefore, a well-designed controlled trial is warranted.